Ignite Creation Date:
2024-05-05 @ 10:26 PM
Last Modification Date:
2024-10-26 @ 10:18 AM
Study NCT ID:
NCT01103791
Status:
COMPLETED
Last Update Posted:
2017-05-05
First Post:
2010-04-05
Brief Title:
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP Polymeric Nanoparticle Formulation of Docetaxel in Subjects With Advanced Solid Malignancies
Sponsor:
Samyang Biopharmaceuticals Corporation
Organization:
Samyang Biopharmaceuticals Corporation
Study Overview
Official Title:
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP Polymeric Nanoparticle Formulation of Docetaxel in Subjects With Advanced Solid Malignancies
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose of docetaxel-PNP polymeric nanoparticle formulation of docetaxel and to evaluate the safety and pharmacokinetics of docetaxel-PNP in subjects with advanced solid malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None